ImportantMDT
Explain this story: Is Medtronic (MDT) Reasonable On Cash Flow After Its $700 Million Robotics Bet?
Medtronic (MDT) shares have returned 25.2% over the past three years, prompting a review of whether its current share price aligns with its expected cash flows. Despite recent regulatory milestones and a $700 million robotics partnership, the stock's valuation, based on a Discounted Cash Flow (DCF) model, suggests it is meaningfully undervalued compared to its current price of $86.44. The DCF model indicates future cash flows support a higher intrinsic worth, with the upfront cost of the robotics partnership partially explaining the current price lag.
OtherSimply Wall StreetSector and industry: HealthcareMedical DevicesTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Medtronic (MDT) shares have returned 25.2% over the past three years, prompting a review of whether its current share price aligns with its expected cash flows. Despite recent regulatory milestones and a $700 million robotics partnership, the stock's valuation, based on a Discounted Cash Flow (DCF) model, suggests it is meaningfully undervalued compared to its current price of $86.44. The DCF model indicates future cash flows support a higher intrinsic worth, with the upfront cost of the robotics partnership partially explaining the current price lag.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Oct 1, 2026, 20:57 ET · on this site +1h 5m